Abstract
The number of individuals receiving genetic counseling for hereditary breast and ovarian cancer syndrome has steadily risen. To triage patients for genetic counseling and to help reduce the amount of time needed by a genetic counselor in direct patient contact, many clinics have implemented the use of family history questionnaires. Although such questionnaires are widely used, scant literature exists evaluating their effectiveness. This article explores the extent to which family history questionnaires are being used in Ontario and addresses the utility of such questionnaires in one familial cancer clinic. By comparing the pedigrees created from questionnaires to those updated during genetic counseling, the accuracy and effectiveness of the questionnaires was explored. Of 121 families recruited into the study, 12% acquired changes to their pedigree that led to a revised probability estimate for having a BRCA1 or BRCA2 mutation and 5% acquired changes that altered their eligibility for genetic testing. No statistically significant difference existed between the eligibility for genetic testing prior to and post counseling. This suggests that family history questionnaires can be effective at obtaining a family history and accurately assessing eligibility for genetic testing. Based on the variables that were significantly associated with a change in probability estimate, we further present recommendations for improving the clarity of such questionnaires and therefore the ease of use by patients.
Similar content being viewed by others
References
Antoniou, A., Pharoah, P. D., Narod, S., et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics, 72, 1117–1130. doi:https://doi.org/10.1086/375033.
Berry, D. A., Iversen, E. S,. Jr, Gudbjartsson, D. F., Hiller, E. H., Garber, J. E., Peshkin, B. N., et al. (2002). BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Journal of Clinical Oncology, 20(11), 2701–2712. doi:https://doi.org/10.1200/JCO.2002.05.121.
The Breast Cancer Linkage Consortium. (1999). Cancer risks in BRCA2 mutation carriers. Journal of the National Cancer Institute, 91(15), 1310–1316. doi:https://doi.org/10.1093/jnci/91.15.1310.
Brener, D., Schulz, C., Schluger, A., & Offit, K. (1996). A self-administered family history questionnaire (FHQ) utilized in an outpatient setting to assess cancer risk. American Journal of Human Genetics, 59, A333.
Chalmers, K. I., Luker, K. A., Leinster, S. J., Ellis, I., & Booth, K. (2001). Information and support needs of women with primary relatives with breast cancer: development of the information and support needs questionnaire. Journal of Advanced Nursing, 35(4), 497–507. doi:https://doi.org/10.1046/j.1365-2648.2001.01866.x.
FamyGenetix Ltd. (2001). Cyrillic 3. Oxford: UK.
Ford, D., Easton, D. F., Bishop, D. T., et al. (1994). Risks of cancer in BRCA1-mutation carriers. Lancet, 343, 692–695. doi:https://doi.org/10.1016/S0140-6736(94)91578-4.
Hallowell, N., Murton, F., Statham, H., Green, J. M., & Richards, M. P. (1997). Women's need for information before attending genetic counselling for familial breast or ovarian cancer: a questionnaire, interview, and observational study. BMJ (Clinical Research Ed), 281, 7076–283.
King, M. C., Marks, J. H., Mandell, J. B., & New York Breast Cancer Study Group. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302, 643–646. doi:https://doi.org/10.1126/science.1088759.
Marroni, F., Aretini, P., D’Andrea, E., Caligo, M. A., Cortesi, L., Viel, A., et al. (2004). Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. European Journal of Human Genetics, 12(11), 899–906. doi:https://doi.org/10.1038/sj.ejhg.5201256.
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266(5182), 66–71. doi:https://doi.org/10.1126/science.7545954.
NCIC. (2007). Canadian Cancer Statistics 2007. Toronto: Canada.
Risch, H. A., McLaughlin, J. R., Cole, D. E., Rosen, B., Bradley, L., Kwan, E., et al. (2001). Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics, 68(3), 700–710. doi:https://doi.org/10.1086/318787.
Risch, H. A., McLaughlin, J. R., Cole, D. E., Rosen, B., Bradley, L., Fan, I., et al. (2006). Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. Journal of the National Cancer Institute, 98(23), 1694–1706.
Satagopan, J. M., Offit, K., Foulkes, W., Robson, M. E., Wacholder, S., Eng, C. M., et al. (2001). The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiology, Biomarkers & Prevention, 10(5), 467–473.
Thorlacius, S., Struewing, J. P., Hartge, P., Olafsdottir, G. H., Sigvaldason, H., Tryggvadottir, L., et al. (1998). Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet, 352(9137), 1337–1339. doi:https://doi.org/10.1016/S0140-6736(98)03300-5. see comment.
Whittemore, A. S., Gong, G., & Itnyre, J. (1997). Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. American Journal of Human Genetics, 60(3), 496–504.
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, 378(6559), 789–792. doi:https://doi.org/10.1038/378789a0.
Ziogas, A., & Anton-Culver, H. (2003). Validation of family history data in cancer family registries. American Journal of Preventive Medicine, 24(2), 190–198. doi:https://doi.org/10.1016/S0749-3797(02)00593-7.
Acknowledgments
The authors wish to acknowledge Kara Hitchman for her excellent comments and contributions to reviewing the manuscript.
Author information
Authors and Affiliations
Corresponding author
Appendices
Appendix I: BRCA1/BRCA2 Genetic Testing Criteria in the Province of Ontario
Testing for affected individuals with breast or ovarian cancer
At least one case of cancer:
-
1.
Ashkenazi Jewish and breast cancer <50 years, or ovarian cancer at any age. Note: testing limited to ethnic specific mutations, unless other criteria given in this list are met.
-
2.
Breast cancer <35 years of age.
-
3.
Male breast cancer.
-
4.
Invasive serous ovarian cancer at any age.
At least two cases of cancer on the same side of the family:
-
5.
Breast cancer <60 years, and a first or second-degree relative with ovarian cancer or male breast cancer.
-
6.
Breast and ovarian cancer in the same individual, or bilateral breast cancer with the first case <50 years.
-
7.
Two cases of breast cancer, both <50 years, in first or second-degree relatives.
-
8.
Two cases of ovarian cancer, any age, in first or second-degree relatives.
-
9.
Ashkenazi Jewish and breast cancer at any age, and any family history of breast or ovarian cancer. Note: testing limited to ethnic specific mutations, unless other criteria given in this list are met.
At least three cases of cancer on the same side of the family:
-
10.
Three or more cases of breast or ovarian cancer at any age.
Testing for unaffected individuals (this should be done only if affected individuals are unavailable e.g. deceased)
-
11.
Relative of individual with known BRCA1 or BRCA2 mutation. Note: specific family mutation only tested.
-
12.
Ashkenazi Jewish and first or second-degree relative of individual with: breast cancer <50 years, or ovarian cancer at any age, or male breast cancer, or breast cancer at any age, with positive family history of breast or ovarian cancer. Note: testing limited to ethnic specific mutations, unless other criteria are met.
-
13.
A pedigree strongly suggestive of hereditary breast/ovarian cancer, i.e. risk of carrying a mutation for the individual being tested is >10%.
Appendix II: Revised Family History Questionaire
Rights and permissions
About this article
Cite this article
Randall Armel, S., McCuaig, J., Finch, A. et al. The Effectiveness of Family History Questionnaires in Cancer Genetic Counseling. J Genet Counsel 18, 366–378 (2009). https://doi.org/10.1007/s10897-009-9228-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10897-009-9228-x